Pegylated liposomal doxorubicin
Contents
Regimen
Kaposi's Sarcoma
- Pegylated liposomal doxorubicin (Doxil) 20 mg/m2 iv
- Q3w
References
Northfelt DW et al. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi’s sarcoma after failure of standard chemotherapy. J Clin Oncol 1997; 15:653
Sarcoma
- Pegylated liposomal doxorubicin (Doxil) 50 mg/m2 iv over 1 h q4w
References
Judson, I et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL(R)/CAELYX(R)) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma. a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2001; 37:870
Indication
Ovarian Epithelial Cancer
Chemotherapy for recurrent or metastatic cancer
- Pegylated liposomal doxorubicin (Doxil) 50 mg/m2 iv over 1 h
- Q4w
References
Mutch DG et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 2007; 25:2811
Gordon, AN et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 2000; 18:3093
